M42, Juvenescence partner to develop AI-powered therapeutics

Abu Dhabi healthtech M42 and British clinical-stage drug development company Juvenescence have joined forces to create and develop a pipeline of AI-powered therapeutics aimed at extending healthy lifespan and advancing the treatment of life-threatening diseases.

By combining M42’s expertise in genomics, biobanking, and clinical trial infrastructure with Juvenescence’s AI-driven discovery technology and extensive drug development experience, the partnership is expected to drive breakthroughs in life sciences research, enhance understanding of diseases, and expedite clinical trials.

The collaboration will bring together Juvenescence’s team of scientists and industry leaders, who collectively possess over 150 years of experience in drug discovery and development. Together with M42, they will work to build an innovative therapeutics pipeline.

Through this collaboration, M42 is leveraging its genomics capabilities, developed in partnership with the Department of Health Abu Dhabi (DoH), to push forward advancements in disease understanding and precision medicine.

This expansion into AI-enabled therapeutics supports Abu Dhabi’s broader ambition to become a global hub for AI-driven longevity science and next-generation drug development.

The announcement was made during Abu Dhabi Global Health Week.